Effective drugs on the road to HCV elimination and a therapeutic gap to close

Affiliations

¹ Eijkman Institute for Molecular Biology, Jakarta 14240, Indonesia; Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia; Faculty of Medicine and Health, University of Sydney, NSW, Australia. Electronic address: davidhm@eijkman.go.id.

Comment

David H Muljono. Lancet Gastroenterol Hepatol. 2019 Feb.

. 2019 Feb;4(2):86-88.

doi: 10.1016/S2468-1253(18)30417-5. Epub 2018 Dec 14.

¹ Eijkman Institute for Molecular Biology, Jakarta 14240, Indonesia; Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia; Faculty of Medicine and Health, University of Sydney, NSW, Australia. Electronic address: davidhm@eijkman.go.id.

No abstract available

Comment on

Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
Wei L, Lim SG, Xie Q, Văn KN, Piratvisuth T, Huang Y, Wu S, Xu M, Tang H, Cheng J, Le Manh H, Gao Y, Mou Z, Sobhonslidsuk A, Dou X, Thongsawat S, Nan Y, Tan CK, Ning Q, Tee HP, Mao Y, Stamm LM, Lu S, Dvory-Sobol H, Mo H, Brainard DM, Yang YF, Dao L, Wang GQ, Tanwandee T, Hu P, Tangkijvanich P, Zhang L, Gao ZL, Lin F, Le TTP, Shang J, Gong G, Li J, Su M, Duan Z, Mohamed R, Hou JL, Jia J. Wei L, et al. Lancet Gastroenterol Hepatol. 2019 Feb;4(2):127-134. doi: 10.1016/S2468-1253(18)30343-1. Epub 2018 Dec 14. Lancet Gastroenterol Hepatol. 2019. PMID: 30555048 Clinical Trial.